HMGB1 Review: HMGB1 – a potential target for the treatment of hematological malignancies

HMGB1 is a broad DNA-binding protein involved in maintaining gene stability, regulating DNA transcription and repair. HMGB1 could bind to PRR receptors such as RMP, TLR and CXCL12 by activating CDC42, MyD88 / TRAF6, NF-kB, MAPK and anti-apoptotic protein c-IAP in the presence of injury, infection and chemotherapy. And other ways to mediate inflammatory response, angiogenesis and tumor cell growth and metastasis, to promote tumor development and participation in T cell-dependent immune response, play an immune effect. HMGB1 interacts with Beclin1, ERK, JNK and other proteins to promote autophagy of blood malignancy (exogenous HMGB1), and HMGB1 can inhibit the proliferation of malignant cells. Direct induction of autophagy), involved in chemotherapy, radiotherapy resistance. Therefore, by inhibiting the expression of HMGB1, promote tumor cell apoptosis and increase the sensitivity of blood cells to chemotherapy drugs, is a new strategy for the treatment of hematological malignancies.

Reference

1: Bachireddy P, Burkhardt UE, Rajasagi M, Wu CJ. Haematological malignancies: at
the forefront of immunotherapeutic innovation. Nat Rev Cancer. 2015
Apr;15(4):201-15. doi: 10.1038/nrc3907. Epub 2015 Mar 19. Review. PubMed PMID:
25786696; PubMed Central PMCID: PMC4511812.

Check HMGB1 knowledge base and HMGB1 ELISA kit review

Leave a Reply